title: Usefulness of pp65 antigenemia for the early diagnosis of cytomegalovirus disease in patients with AIDS.
abstract: An observational cohort study was performed to assess the effectiveness of a cytomegalovirus antigenemia (CMV-Ag) assay designed to predict clinical CMV disease in patients with AIDS. Eighty-six HIV-infected patients with CD4+ cell counts of < 100/mm3, positive CMV IgG, and no previous CMV disease were enrolled. Thirty-eight (44%) patients had at least one positive CMV antigenemia test, ten of whom eventually developed CMV focal disease. CMV disease was diagnosed in 13 (15%) patients. The CMV antigenemia assay was positive in ten of these 13 patients. Using a cut-off value of five positive cells in every 150,000 leukocytes sampled, the CMV antigenemia assay had a positive predictive value of 89% and a negative predictive value of 94%. The median time from the first positive CMV antigenemia test to the onset of CMV disease was 102 days. CMV disease probability at 6 months in patients with a CMV antigenemia value > or = 5 was 77.8% versus 6% in patients with CMV antigenemia value < 5 (log-rank test = 48.345; P < 0.001). Several independent factors were associated with the development of CMV disease: CMV antigenemia > or = 5 cells (hazard ratio: 20.44), CD4+ count < or = 25/mm3 (HR: 3.12), and sexual transmission of HIV infection (hazard ratio, 3.15). CMV antigenemia seems to be a good predictor of CMV disease in patients with AIDS.
authors.affiliation: Servicio de Medicina Interna, Sección de Enfermedades Infecciosas, Hospital General Universitario de Alicante, Spain. karmen@umh.es
authors.forename: D
authors.initials: D
authors.lastname: Torrús
authors.forename: J
authors.initials: J
authors.lastname: Portilla
authors.forename: I
authors.initials: I
authors.lastname: Hernández-Aguado
authors.forename: V
authors.initials: V
authors.lastname: Boix
authors.forename: J
authors.initials: J
authors.lastname: Plazas
authors.forename: A
authors.initials: A
authors.lastname: Gimeno
authors.forename: M
authors.initials: M
authors.lastname: Torromé
authors.forename: C
authors.initials: C
authors.lastname: Llopis
authors.forename: V
authors.initials: V
authors.lastname: Valls
authors.forename: J
authors.initials: J
authors.lastname: Sánchez-Payá
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000175:diagnosis* / Q000276:immunology / Q000821:virology; D000328:Adult; D000956:Antigens, Viral / Q000097:blood*; D018791:CD4 Lymphocyte Count; D003587:Cytomegalovirus / Q000276:immunology*; D003586:Cytomegalovirus Infections / Q000175:diagnosis*; D004279:DNA, Viral / Q000032:analysis; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010750:Phosphoproteins / Q000097:blood*; D016133:Polymerase Chain Reaction; D014763:Viral Matrix Proteins / Q000097:blood*
chemical_list: D000956:Antigens, Viral; D004279:DNA, Viral; D010750:Phosphoproteins; D014763:Viral Matrix Proteins; C065418:cytomegalovirus matrix protein 65kDa